ArticleFrontiers in pharmacology2025
Methodological study protocol for The European Atlas of clinical trials in cancer and haematology.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Inequalities in access to clinical trials in cancer, haematology and rare diseases, along with the inconsistent incorporation and reporting of patient reported outcome measures (PROMs) are a long-addressed issue by patient communities. The European Atlas on Clinical Trials in Cancer and Haematology (EuroACT) is a patient-led investigation assessing regional inequalities in access to clinical trials, the frequency and type of patient reported outcome (PRO) data collection in trials, and the reporting of PRO findings in selected solid tumours, malignant/non-malignant haematological conditions and rare diseases across Europe. Methods and analysis: This protocol outlines the development of three comprehensive datasets [i.e., clinical trials, patient reported outcome and experience measure (PROM, PREM), and publication datasets] along research questions and analysis plan for the EuroACT study. Data for the analysis were sourced from public clinical trial registries (e.g., EudraCT, ClinicalTrials.gov), PRO databases, and published literature, and were subsequently processed in several steps, including standardisation, enrichment, and merging. The analysis plan is organised into three workstreams, each focusing on hypotheses related to the geographical distribution of clinical trials, the use of PROMs in trials, and the frequency of PRO data publication, addressing multiple primary and sub-research questions. The EuroACT study has been co-developed with the patient community, involving a steering group of patient representatives at each step. Results: A dataset of interventional trials and observational studies with European sites resulted containing 11,185 trials and 1.8 million data points for interventional trials, and 3,723 trials and 2,200 data points for observational studies. The PROM/PREM dataset contains information on 631 PROMs and 14 PREMs. The publication dataset development resulted in a comprehensive dataset containing information on 14,484 scientific publications. Discussion: The EuroACT research project integrates high-quality data sources, including EudraCT and ClinicalTrials.gov (NCT), with advanced data processing techniques. The data access and processing workflows were developed to enhance transparency, reproducibility, and reliability, while also laying the groundwork for future automation efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.